Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.…
Elicio Therapeutics: Q3 Earnings Snapshot
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Elicio Therapeutics (NASDAQ: ELTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 33 employees.
The shares were at 1.450 USD on 20 November 2026, down 83.7% over 52 weeks. Its 52-week range is 1.250 USD to 16.00 USD: the price is 90.9% below the high and 16.0% above the low.
Its market capitalisation is 41.05M USD.
Elicio Therapeutics reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 16.91M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.